Charles River UK Ltd

CRADL, London can support Biotech companies, Pharma, spin offs and academic groups in their drug discovery platforms in a cost effective way and mitigating risks to funding programmes.

With more than 150 sites in 21 countries, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving your product’s unique challenges. Our focus on timeliness and accuracy in every stage of development means you can count on reliable, reproducible results – throughout your journey. Customers: Leading pharmaceutical, biotechnology, agrochemical, government, and academic organizations around the world Service Areas: Basic research, discovery, safety and efficacy, clinical support, and manufacturing.

• Small molecules
• Musculoskeletal Disorders
• Immunology/inflammation
• Fibrosis
• Engineered Biology
• Medical Devices
• Gastrointestinal Tract
• Blood
• Reproductive Health
• Diabetes
• Neurology
• Platform Technology
• Allergic Disorders
• Eye Health
• Virology
• Antimicrobial Resistance
• Autoimmune diseases
• Respiratory System
• Generics
• Mental Health and Depression
• Dermatology
• Stem Cells/Regenerative Medicine
• Oncology
• Ear
• Nose and Throat
• Central Nervous System
• Poisoning and Drug Dependence
• Dementia
• Metabolic Disorders
• Digital Health
• Translational Medicine
• Cardiovascular System
• Enzyme
• Endocrinology
• Biomarkers
• ATMP